Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion

SIMPLE SUMMARY: We assessed the efficacy and safety of low-dose apatinib monotherapy as a third-line treatment in patients with metastatic colorectal cancer. The ORR and DCR were 4.0% (2/50) and 70% (35/50), and the median PFS and OS were 4.7 months and 10.1 months, which demonstrated comparable sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lingying, Yu, Qiang, Gao, Chunyi, Xiang, Jingzhou, Zheng, Bowen, Feng, Yujie, Li, Runyang, Zhang, Wenqing, Hong, Xiaoting, Zhan, Yan-yan, Xiao, Li, Hu, Tianhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139438/
https://www.ncbi.nlm.nih.gov/pubmed/35626097
http://dx.doi.org/10.3390/cancers14102492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139438/
https://www.ncbi.nlm.nih.gov/pubmed/35626097
http://dx.doi.org/10.3390/cancers14102492

Ejemplares similares